Detalles de la búsqueda
1.
Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
Cancer
; 128(12): 2358-2366, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35417563
2.
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
J Cancer Res Clin Oncol
; 149(7): 3267-3276, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35915184
3.
Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports.
Expert Opin Investig Drugs
; 32(3): 187-200, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36780358
4.
Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
J Cancer Res Clin Oncol
; 149(10): 7393-7403, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36939927
5.
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study.
Transl Lung Cancer Res
; 11(7): 1503-1509, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958344
6.
NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer.
Transl Lung Cancer Res
; 11(4): 702-705, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35529786
Resultados
1 -
6
de 6
1
Próxima >
>>